Qynapse - The future of neuroimaging is here
  • WHY QYNAPSE
  • I AM
    • Patient or Caregiver
    • Healthcare Provider
    • Pharma
    • Payer
  • PRODUCTS
    • QyScore®
    • QyPredict®
  • COMPANY
    • Team
    • Careers
  • NEWS
    • News & Press Releases
    • Publications
  • CONTACT
Select Page
Qynapse and Amsterdam UMC Publish Landmark Study in Alzheimer’s Research & Therapy

Qynapse and Amsterdam UMC Publish Landmark Study in Alzheimer’s Research & Therapy

by Aline Fieck | May 6, 2025 | Featured, News

PARIS, FRANCE, May 6, 2025 – We are thrilled to share that Qynapse’s collaborative study with Amsterdam UMC has been published in Alzheimer’s Research & Therapy: “Clinical phenotypes of Alzheimer’s disease: investigating atrophy patterns and their pathological...
Qynapse presents at the International Conference on Alzheimer’s and Parkinson’s disease and Related Neurological Disorders AD/PD 2025

Qynapse presents at the International Conference on Alzheimer’s and Parkinson’s disease and Related Neurological Disorders AD/PD 2025

by Aline Fieck | Apr 5, 2025 | Featured, News

PARIS, FRANCE, April 5, 2025 –Dr. Luca Villa, Senior Clinical Scientist, presented our work focused on using QyScore® and QyPredict® to differentiate patients with progressive supranuclear palsy from patients with Parkinson’s disease.    The presentation, titled...
Qynapse participates in “Challenges of AI in Healthcare”

Qynapse participates in “Challenges of AI in Healthcare”

by Aline Fieck | Feb 12, 2025 | Featured, News

PARIS, FRANCE, February 12, 2024 – Qynapse had the pleasure of participating in “Challenges of AI in Healthcare”, an event organized by PariSanté Campus and French Healthcare Association as part of the AI Action Summit in Paris.   This gathering brought...
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

by Aline Fieck | Jan 15, 2025 | Featured, News

PARIS, FRANCE, January 15 28, 2025 – Qynapse congratulates Anavex Life Sciences on the peer-reviewed publication of the ANAVEX®2-73-AD-004 Phase IIb/III clinical trial in The Journal of Prevention of Alzheimer’s Disease. This 48-week randomized, placebo-controlled...

Careers

Qynapse Office Locations

Expanding Global Presence

Healthcare, Clinical Trial and Research Footprint

QYNAPSE (PARIS)
2-10 rue d’Oradour-sur-Glane
75015 Paris – France

QYNAPSE (BOSTON)
50 Milk St
Boston, MA, 02119 – USA

QYNAPSE (MONTREAL)
7240 Waverly St, Montreal,
Quebec H2R 2Y8 – Canada

contact@qynapse.com

  • Follow
  • Follow

Qynapse is ISO 13485, ISO/IEC27001 and HDS Certified, HIPAA Compliant, GDPR Compliant, and 21 C.F.R. Part 11 Compliant | QyScore® is FDA-Cleared, CE-Marked (CE2797) | Privacy Policy | ©2025 QYNAPSE ALL RIGHTS RESERVED. Last update: Jan 30. 2023

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT